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INTRODUCTION 
Congestive heart failure (CHF) continues to be a major 
clinical and public health problem with shift in etiology 
from hypertension, valvular heart disease to ischemia. It 
is a condition that can result from any structural or 
functional cardiac disorder that impairs the ability of the 
heart to fill with or pump a sufficient amount of blood 
through the body. The most common cause is coronary 
heart disease
1
(CHD), especially myocardial infarction 
(MI).Others include hypertension, valve disease, 
cardiomyopathy and arrhythmias, particularly atrial 
fibrillation
2,3.
Infections, anaemia and thyrotoxicosis can 
exacerbate, but also occasionally cause heart failure. 
Independent risk factors include diabetes, smoking, 
obesity, left ventricular hypertrophy or asymptomatic 
left ventricular dysfunction 
2,4
. Heart failure is most 
commonly due to an enlarged and poorly contracting 
left ventricle, known as systolic heart failure
. 5, 6
 
Reduced left ventricular emptying leads to a fall in 
cardiac output, which triggers compensatory 
mechanisms. These effects paradoxically have a role in 
the progression of chronic heart failure 
6,
 and contribute 
to common symptoms Such as dyspnoea oedema, 
fatigue, lethargy and exercise intolerance. Heart 
failuremay lead to various complications, including 
arrhythmias; thromboembolism and pulmonary 
congestion atrial fibrillation (AF) may be the cause or 
consequence of heart failure and is present in about a 
third of patients. Treatment of CHF aims to relieve 
symptoms, maintain a euvolemic state and to improve 
prognosis by delaying progression of heart failure and 
reducing cardiovascular risk. Drugs used include: 
diuretic agents, vasodilator agents, positive inotropes, 
ACE inhibitors, beta blockers, and aldosterone 
antagonists. Beta blockers have been evaluated in 
nearly 10, 000 patients with chronic heart failure in over 
20 randomised clinical trials and have been shown to 
decrease the risk of death and the need for hospital 
admission and to improve patients clinical status. These 
benefits were attained in patients already taking ACE 
inhibitors and diuretics (with or without digitalis), with 
ischemic and non-ischemic disease and with different 
degrees of functional impairment. Until recently, beta 
blockers were contraindicated in the treatment of CHF, 
largely because heart failure was viewed primarily as a 
hemodynamic disorder.  
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ABSTRACT: 
Background and objectives: Congestive heart failure (CHF) continues to be a major clinical and public health problem with 
shift in etiology from hypertension, valvular heart disease to ischaemia. Carvedilol is a non-selective beta-blocker with α1- 
blocking activity. In the present study, the efficacy of Carvedilol, by assessing the baseline left ventricular ejection fraction 
heart rate, and  blood pressure. 
Materials and methods: A total number of 40 patients were enrolled in the study, 20 were heart failure patients and 20 were 
age-sex matched controls (not receiving carvedilol). After the study period of 24 weeks, the efficacy of carvedilol in reducing 
heart rate, systolic blood pressure, diastolic blood pressure and left ventricular ejection fraction were evaluated. 
Results: Carvedilol when given in low doses, was effective in increasing left ventricular ejection fraction  from (31.73 ± 2.28 
%) to (40.85 ± 7.51 %) with p< 0.0001, decreasing heart rate from (80.95 ± 5.10) to (71.50 ± 6.11) beats / min, with p<0.0001, 
and reducing systolic blood pressure 5.25 ± 4.99 with p<0.0006and diastolic blood pressure 6.50 ± 6.71 with p<0.4077 
Conclusion: Carvedilol is a non-selective beta-blocker with α1- blocking activity and when given in low doses, increases 
cardiac ejection fraction, decreases ventricular mass, improves the shape of the ventricle, and reduces systolic and diastolic 
volumes. In conclusion from our study, Carvedilol increases the baseline left ventricular ejection fraction and heart rate more 
significantly in the patients than in the controls. 
Keywords: Congestive heart failure (CHF), Carvediloleffect on blood pressure, increases cardiac ejection fraction 
Balkrishna et al                                   Journal of Drug Delivery & Therapeutics. 2015; 5(1):65-69 66 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
Although drugs with positive inotropic effects can 
produce short-termsymptomatic improvements in 
patients with heart failure, their long-term use does not 
prolong life
 7.
 
As the failing heart depends on β-adrenergic support to 
maintain its performance, acute pharmacological effects 
of any antiadrenergic compound may induce 
myocardial depression and a decrease in cardiac output. 
Although such effects may be counteracted by the 
vasodilator properties of some β- blocking drugs, which 
by reducing systemic vascular resistance could 
counteract myocardial depression, an abrupt 
suppression of adrenergic support may initially 
precipitate a clinical worsening of heart failure. 
Nevertheless, this negative pharmacological response is 
transitory and manageable by administration of initial 
low doses and gradual dosage increase 
8.
 Additionally, 
chronic effects of β-blocking agents differ from the 
acute effects because they result essentially from the 
inhibition of neurohormonal responses that aggravate 
heart failure, favourably changing myocardium biology 
9]
.It has been recently hypothesized that heart failure is 
an entity with a progressive decline in ventricular 
function due to progressive myocyte dysfunction 
(caused by gene expression changes), loss of cells (due 
to necrosis and apoptosis), and subsequent cell and 
cardiac chamber remodelling
[10].
 The remodelling 
process results in ventricular enlargement, an increase 
in wall stress, relative myocardial ischemia, energy 
depletion, progressive interstitialfibrosis, and additional 
activation of sympathetic nervous and renin 
angiotensin-aldosterone systems
10
. Cardiac sympathetic 
activity increase and elevated neither plasma nor 
epinephrine levels are reactions that occur early in heart 
failure patients. They may be already detected in 
asymptomatic left ventricular dysfunction
11
 and 
increase as the syndrome progresses 
12
. Sympathetic 
activation leads to an increase in heart rate, arteriolar 
vasoconstriction, and peripheral vascular resistance and 
to a decrease in blood flow and sodium excretion 
consequently increasing ventricular volume and 
pressure. Cardiac work and oxygen consumption 
increase. Nor epinephrine may induce myocardial 
hypertrophy, but reduces coronary circulation’s ability 
to adequately supply blood to an enlarged ventricular 
wall, leading to myocardial ischemia
13.
 Additionally, 
norepinephrine exerts direct toxic effects on the 
myocardium, causing myocyte dysfunction and necrosis 
by several mechanisms. β1-and β2-receptor stimulation 
provokes cyclic adenosine monophosphate (cAMP)-
mediated calcium overload in cardiac myocytes, and 
activates calcium-dependent ATPases, decreasing the 
availability of highlyenergetic phosphates, further 
worsening mitochondrial function
14.
 In addition, by 
stimulating growth andoxidative stress in terminally 
differentiated cells, norepinephrine can trigger 
apoptosis 
15.
Several studies have demonstrated that 
elevated cardiac sympathetic activity is one of the 
leading causes of the progressive decline in myocardial 
function and of a poor prognosis in heart failure patients 
16
.Hence the recognition of deleterious effects provoked 
by the sympathetic nervous system in left ventricular 
systolic function and the potential inhibition of 
sympathetic-adrenergic stimulationby chronic therapy 
with β-blocking drugs led to an increased administration 
of such drugs in heart failure management.Carvedilol is 
a nonselective beta-adrenoreceptor antagonist and an 
alpha1-adrenoreceptor antagonist and a potent 
antioxidant. It has no intrinsic sympathomimetic 
activity. The beta-blocking actions of carvedilol are 
generally evident in humans within one hour of 
administration, and the alpha-mediated vasodilatory 
effects, manifested by decreased peripheral resistance 
and decreased blood pressure, are evident within about 
30 minutes of administration. At high dosages, 
carvedilol exerts calcium channel blocking activity. It 
also has significant antioxidant properties. Carvedilol 
inhibits the generation of oxygen free radicals and 
prevents low-density lipoprotein (LDL) oxidation, 
which, in turn, reduces the uptake of LDL into the 
coronary vasculature. This antioxidant activity may 
contribute to carvedilol's cardio protective effects. 
Carvedilol improves left ventricular function (LVEF) 
and to reduce mortality .The starting dosage of 
carvedilol is 3.125 mg orally twice daily for two weeks. 
Carvedilol should be taken with food to reduce the 
incidence of orthostatic hypotension. Patients should be 
observed for adverse reactions, especially dizziness, 
light headedness and hypotension, for one hour after the 
first dose and again after each dosage increase. Blood 
pressure should be measured with the patient standing. 
Patients should be instructed to weigh themselves every 
day and to contact their physician immediately if they 
experience a weight gain. The dosage should be 
doubled every two weeks to the maximum dosage or the 
highest tolerated dosage. The maximum recommended 
dosage for carvedilol is 25 mg twice daily in patients 
weighing less than 85 kg and 50 mg twice daily in 
patients weighing 85 kg or more. 
AIMS AND OBJECTIVES 
 To study the effect of beta blocker on the left 
ventricular ejection fraction. 
 To describe its effect on the heart rate. 
 To observe the effect of Carvedilol on blood 
pressure. 
MATERIALS AND METHODS 
The study was conducted with the joint collaboration of 
M.G.M Hospital and the Department of Pharmacology, 
Kakatiya Medical College, Warangal. The study 
protocol was approved by the institutional ethical 
committee. All the subjects enrolled into the study gave 
written informed consent for their participation. All 
male and female patients between 30 to 85 years of age, 
diagnosed with heart failure falling into the category of 
functional New York Heart Association (NYHA) class 
II or III with left ventricular ejection fraction (LVEF) ≤ 
35% were included in the study. Patients were excluded 
if they had a history of drug sensitivity or allergic 
reaction to alpha or beta-blockers, contraindication or 
intolerance to beta-blockers, pregnant or lactating 
women and women planning to become pregnant, 
history of asthma or severe chronic obstructive 
pulmonary disease; severe liver or kidney diseases, 
patients unwilling to provide written informed consent 
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second-degree or third degree heart block and sick sinus 
syndrome. 
A total number of 40 patients were enrolled in the 
study, 20 in control group (patients not receiving 
carvedilol or placebo, but were receiving therapy as 
prescribed by the physician) and 20 in carvedilol group. 
All the patients were evaluated for demographic data, 
laboratory profile, clinically features and non invasively 
for LV function by echo cardiogram (for ejection 
fraction) at baseline and at end of treatment after 24 
weeks 
Statistical Analysis 
Data was entered into excel spread sheet-7. Continuous 
data was described as mean and standard deviation and 
unpaired and paired t test was used to infer the data 
between the two groups and within groups respectively. 
A two tailed p value < 0.05 was considered statistically 
significant. Sample size was calculated based on an 
increase in LVEF by 3.5%. with 80% power and one-
sided alpha error of 0.05. A total of sixteen patients per 
group will be required. To account for lost to follow-up 
of patients we considered 20 patients per group. 
RESULTS 
In the Beta Blocker study group out of total of 40 
subjects, 20 were heart failure patients and 20 were age 
and gender matched controls. There were 13 males and 
7 females in the Carvedilol group and 14 males and 6 
females in the control group. Evaluation of the base line 
demographic parameters of the Beta blocker wing 
shows that there is no statistically significant difference;  
Age (56.80 ± 3.41 vs. 60.10 ± 6.3 yrs; p=0.0613); 
Height (1.59 ± 0.06 vs. 1.58 ± 0.06 m; p=0.4613); 
Weight (65.55 ± 4.45 vs. 61.55 ± 5.27 kg; 
p=0.5376);and 
Body mass index (24.75 ± 2.82 vs. 24.84 ± 3.10 m/kg
2
; 
p=0.9339); 
Between the Carvedilol group and the control group 
respectively. (Table-1) 
 
Table 1: Demographic data 
 Carvedilol Control p-Value 
Gender M-13 / F-7 M-14 / F-6 1.000 
Age (yrs) 56.80 ± 3.41 60.10  ± 6.3 0.0613 
Height (m) 1.59 ± 0.06 1.58  ± 0.06 0.4613 
Weight (kg) 65.55 ± 4.45 61.55  ± 5.27 0.5376 
Body Mass Index cm/kg
2
 24.75 ± 2.82 24.84  ± 3.10 0.9339 
  
Table-2shows that the mean change in the heart rate in 
the Carvedilol group is significant with (9.45 ± 7.25) 
beats / min; to a change of (3.20 ± 3.16) beats / min in 
the control group, with p=0.0024 (Graph-1).  
Likewise the effect on the left ventricular ejection 
fraction is also more significant in the Carvedilol group 
than the control group, with a change from (-9.12 ± 
7.33) vs. (-3.43 ± 2.94) respectively (Graph-2).   
 
Table 2: Carvedilol Vs Control 
S.NO VARIABLE Carvedilol Group Control Group p-Value 
1. Heart Rate 9.45 ± 7.25 3.20 ± 3.16 0.0024 
2. Systolic Blood Pressure 5.25 ± 4.99 13.75 ± 9.01 0.0006 
3. Diastolic Blood Pressure 6.50 ± 6.71 8.50 ± 7.45 0.4077 
4. Left Ventricular Ejection Fraction -9.12 ± 7.33 -3.43 ± 2.94 0.0017 
 
 
Graph 1 
 
Graph 2 
Balkrishna et al                                   Journal of Drug Delivery & Therapeutics. 2015; 5(1):65-69 68 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
Table-3 shows the per se effect of Beta blocker 
(Carvedilol) which is shown to decrease the heart rate 
from (80.95 ± 5.10) to (71.50 ± 6.11) beats / min, with 
p<0.0001, compared to decrease from (77.50 ± 4.10) to 
(74.30 ± 3.15) beats / min, with p<0.0002,in the control 
group (Graph-3). 
It is also seen that it significantly raises the left 
ventricular ejection fraction from (31.73 ± 2.28 %) to 
(40.85 ± 7.51 %) with p< 0.0001, in comparison to an 
increase from (30.35 ± 3.7) to (33.78 ± 3.55) in the 
control group (Graph-4). 
Table 3: Effect of Carvedilol 
S.N. VARIABLE 
Carvedilol Group Control Group 
Before After p-Value Before After p-Value 
1. Heart Rate 80.95 ± 5.10 71.50 ± 6.11 < 0.0001 77.50 ± 4.10  74.30 ± 3.15 0.0002 
2. Systolic Blood Pressure 132.0 ± 8.94 126.75 ±10.04 0.0002 133.0 ± 9.23 
119.25 ± 
10.55 
< 0.0001 
3. Diastolic Blood Pressure 86.00 ± 6.81 79.50 ± 6.05 0.0004 81.50 ± 7.45 73.0 ± 4.7 < 0.0001 
4. 
Left Ventricular Ejection 
Fraction 
31.73 ± 2.28 40.85 ± 7.51 < 0.0001 30.35 ± 3.7 33.78 ± 3.55 < 0.0001 
 
 
Graph 3 
 
Graph 4 
DISCUSSION 
The present study was conducted with the evaluation of 
the effects of the beta blocker which was most 
commonly prescribed in our setup in heart failure 
condition, which in our case turned out to be Carvedilol.  
For the Beta blocker wing, the patients who were 
prescribed Carvedilol were followed up for a period of 
six months after drug titration, and their effects on heart 
rate, systolic blood pressure, diastolic blood pressure 
and left ventricular ejection fraction were studied. 
Carvedilol is a non-selective beta-blocker with α1- 
blocking activity and when given in low doses, this 
beta-blocker increases cardiac ejection fraction, 
decreases ventricular mass, improves the shape of the 
ventricle, and reduces systolic and diastolic volumes 
which was substantiated in our study with Carvedilol, 
wherein we found that the increase in the baseline left 
ventricular ejection fraction and heart rate was much 
more significant in the patients than in the controls.  
Although the specific effects of the sympathetic nervous 
system on the progression of heart failure are unclear, 
beta-blockers appear to confer benefits by inhibiting a 
host of effects from sympathetic activation. For 
example, sympathetic activation can cause peripheral 
vasoconstriction, impair sodium excretion by the 
kidneys, provoke arrhythmias, stimulate growth and 
oxidative stress in terminally differentiated cells, and 
trigger programmed cell death. All of these harmful 
effects are mediated via the α1, β1, and β2-adrenergic 
receptors, at which beta-blockers exert their effects.  
These effects of the beta blockers can be elucidated by 
the long term usage of the drug, with large sample size 
and long duration study design and the ensuing effects 
commented upon. But our study was too small both in 
terms of subjects enrolled and the duration, for 
commenting on the statistical significance of these 
effects. But most of the subjects who have been 
enrolled have reported reduced symptoms, improved 
clinical status and decreased incidence of 
hospitalization.  
Our study helps to contribute to the data that is already 
available and also to compare it with the relevant 
guidelines to make our approach more current in the 
pharmacotherapeutic considerations of the management 
of patients with heart failure. 
CONCLUSION 
Treating heart failure is a challenge to the physician 
because of its rising incidence, high rate of 
hospitalization and mortality and frequent co-morbid 
disease and drug interactions. Carvedilol is a non-
selective beta-blocker with α1- blocking activity and 
when given in low doses, this beta-blocker increases 
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cardiac ejection fraction, , and reduces systolic and 
diastolic volumes which were substantiated in our 
study. 
One of the next steps towards improving heart failure 
management is to investigate the reasons underlying the 
low use of b blockers in general practice and then to 
address these issues with educational programs. Such 
programs are clearly needed to improve heart failure 
management in general practice and should give special 
consideration to the role of b-blockers in the treatment 
of CHF. Effective implementation of these treatments 
on an individual basis should greatly improve the 
outcome of patients who develop heart failure. 
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